ClinicalTrials.gg
Active, not recruitingNCT04550260KUNLUNUpdated Oct 13, 2026

Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC

A Phase 3 interventional study of Durvalumab and Placebo in Esophageal Squamous Cell Carcinoma, sponsored by AstraZeneca. Active, not recruiting at 133 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
640
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 401 studies in Esophageal Squamous Cell Carcinoma with a site in China — 174 open to participants now, 213 under way, 32 of them phase 3. Esophageal Squamous Cell Carcinoma · China.

Enrollment
18th of 351
640 · median 70
Started
2020
with 33 others
Phase 3
52 of 401
20 open now
Primary completion
2027-06
later than 134 of 212 live
Registered
135th of 401
by date

Among the 401 studies in Esophageal Squamous Cell Carcinoma with a site in China, this one is the 18th largest by enrollment of the 351 interventional ones that give a count, is one of 34 that started in 2020, is one of 52 in phase 3, reaches primary completion later than 134 of the 212 other live ones, and was the 135th registered.

Esophageal Squamous Cell Carcinoma

678 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 267 are open to participants now.

Browse Esophageal Squamous Cell Carcinoma studies →

Open to participants now

174 of the 401 studies in Esophageal Squamous Cell Carcinoma with a site in China are open now. Recruiting first, the newest first:

169 more — sign in →

All 174 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 180 Esophageal Squamous Cell Carcinoma studies recruiting now, 83 (46%) set no upper age limit and 76 (42%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 401 studies in Esophageal Squamous Cell Carcinoma with a site in China, or all of them as a file.
02

Study summary

This is a Phase III, randomized, double-blind, placebo-controlled, multi-center international study to assess the efficacy and safety of durvalumab administered concurrently with dCRT in patients with locally advanced, unresectable esophageal squamous cell carcinoma (ESCC).

Read the detailed description

Approximately 600 patients with locally advanced, unresectable ESCC (AJCC 8th cStage II-IVA) will be randomized in a 2:1 ratio to receive either durvalumab + dCRT or placebo + dCRT. The primary objectives of this study are to assess the efficacy of durvalumab + dCRT compared with placebo + dCRT in terms of progression free survival (PFS, per RECIST 1.1 as assessed by BICR) in PD-L1 High population.

03

Conditions studied

  • Esophageal Squamous Cell Carcinoma

Keywords

  • Locally Advanced unresectable ESCC
  • PD-L1
  • Durvalumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years or older at the time of signing the ICF.
  • or cytologically confirmed esophageal squamous cell carcinoma, and present with locally advanced disease (Stage II-IVA).
  • Unresectable or refusing surgery, and has been deemed suitable for definitive chemoradiation therapy.
  • Patients with at least an evaluable lesion per 1.1.
  • Mandatory provision of available tumor tissue for expression analysis.
  • PS 0 or 1.
  • Adequate organ and marrow function.
  • of more than 3 months.

Exclusion criteria

Exclusion Criteria:

  • or cytologically confirmed small cell esophageal carcinoma, esophageal adenocarcinoma or other mixed carcinoma.
  • Prior anti-cancer treatment for ESCC.
  • Patient with a great risk of perforation and massive bleeding.
  • History of allogeneic organ transplantation.
  • Active or prior documented or inflammatory disorders.
  • Uncontrolled intercurrent illness.
  • History of another primary .
  • Active infection including tuberculosis, , , or .
  • Known allergy or to any of the study drugs or any of the study drug .
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
640 participants (actual)

Study arms

  • Experimental
    Arm 1: Durvalumab + definitive CRT

    Durvalumab + concurrent chemoradiation

    Drug: Durvalumab · Drug: cisplatin + fluorouracil · Drug: cisplatin + capecitabine · Radiation: Radiation

  • Placebo comparator
    Arm 2: Placebo + definitive CRT

    Placebo + concurrent chemoradiation

    Drug: Placebo · Drug: cisplatin + fluorouracil · Drug: cisplatin + capecitabine · Radiation: Radiation

Interventions

  • Durvalumab intravenous infusion

    Also known as: MEDI4736

  • DrugPlacebo

    Durvalumab matching placebo for intravenous infusion

  • Drugcisplatin + fluorouracil

    Drug pages: Cisplatin · Fluorouracil

    cisplatin + fluorouracil, as per Standard of Care

  • Drugcisplatin + capecitabine

    Drug pages: Cisplatin · Capecitabine

    cisplatin + capecitabine, as per Standard of Care

  • RadiationRadiation

    50-64Gy in total

06

What researchers measure

Primary outcomes

  1. Progression free survival (PFS) per RECIST 1.1 as assessed by BICR

    To assess the efficacy in terms of PFS in PD-L1 High population

    Time frame: up to approximately 56 months

Secondary outcomes

  1. Overall survival (OS)

    To assess the efficacy in terms of OS in all randomized patients and in PD-L1 High population until the date of death

    Time frame: up to approximately 72 months

  2. Progression free survival (PFS) per RECIST 1.1 as assessed by BICR

    To assess the efficacy in terms of PFS in all randomized patients.

    Time frame: up to approximately 56 months

Other outcomes

  1. Adverse events (AEs)

    To assess the safety and tolerability profile of durvalumab + dCRT compared to placebo + dCRT in patients with ESCC

    Time frame: up to approximately 72 months

07

Study locations

133 sites
  • Research Site
    Atlanta, Georgia 30308, United States
  • Research Site
    Louisville, Kentucky 40217, United States
  • Research Site
    Dallas, Texas 75390, United States
  • Research Site
    Fairfax, Virginia 22031, United States
  • Research Site
    Morgantown, West Virginia 26506, United States
  • Research Site
    Brussels, 1090, Belgium
  • Research Site
    Charleroi, 6060, Belgium
  • Research Site
    Liège, 4000, Belgium
  • Research Site
    Namur, 5000, Belgium
  • Research Site
    Barretos, 14784-400, Brazil
  • Research Site
    Fortaleza, 60430-230, Brazil
  • Research Site
    Porto Alegre, 90050-170, Brazil
  • Research Site
    Porto Alegre, 91350-200, Brazil
  • Research Site
    Rio de Janeiro, 20231-050, Brazil
  • Research Site
    São José do Rio Preto, 15090-000, Brazil
  • Research Site
    Vitória, 29043-260, Brazil
  • Research Site
    Barrie, Ontario L4M 6M2, Canada
  • Research Site
    Greater Sudbury, Ontario P3E 5J1, Canada
  • Research Site
    Anyang, 455000, China
  • Research Site
    Beijing, 100021, China
  • Research Site
    Beijing, 100036, China
  • Research Site
    Bengbu, 233004, China
  • Research Site
    Changsha, 410003, China
  • Research Site
    Changzhi, 46000, China
  • Research Site
    Chengdu, 610042, China
  • Research Site
    Chongqing, 400030, China
  • Research Site
    Fuzhou, 350001, China
  • Research Site
    Fuzhou, 350014, China
  • Research Site
    Guangzhou, 510000, China
  • Research Site
    Guangzhou, 510060, China
  • Research Site
    Hangzhou, China
  • Research Site
    Hefei, 230031, China
  • Research Site
    Huai'an, 223300, China
  • Research Site
    Jieyang, 522000, China
  • Research Site
    Jinan, 250117, China
  • Research Site
    Kunming, 650118, China
  • Research Site
    Liangyugang, 222002, China
  • Research Site
    Nantong, 226361, China
  • Research Site
    Qingdao, 266042, China
  • Research Site
    Quanzhou, 362000, China
  • Research Site
    Shenzhen, 518116, China
  • Research Site
    Tianjin, 300060, China
  • Research Site
    Xi'an, 710061, China
  • Research Site
    Xuzhou, 221000, China
  • Research Site
    Yangzhou, 225001, China
  • Research Site
    Zhengzhou, 450008, China
  • Research Site
    Zhenjiang, 212002, China
  • Research Site
    Besançon, 25030, France
  • Research Site
    Lille, 59000, France
  • Research Site
    Lyon, 69008, France
  • Research Site
    Montpellier, 34070, France
  • Research Site
    Reims, 51100, France
  • Research Site
    Rouen, 76031, France
  • Research Site
    Strasbourg, 67033, France
  • Research Site
    Villejuif, 94805, France
  • Research Site
    Bunkyō City, 113-8431, Japan
  • Research Site
    Chūōku, 104-0045, Japan
  • Research Site
    Hidaka-shi, 350-1298, Japan
  • Research Site
    Hirakata-shi, 573-1191, Japan
  • Research Site
    Hiroshima, 730-8518, Japan
  • Research Site
    Kashiwa, 277-8577, Japan
  • Research Site
    Kitaadachi-gun, 362-0806, Japan
  • Research Site
    Kōtoku, 135-8550, Japan
  • Research Site
    Kumamoto, 860-8556, Japan
  • Research Site
    Maebashi, 371-8511, Japan
  • Research Site
    Matsuyama, 791-0280, Japan
  • Research Site
    Niigata, 951-8566, Japan
  • Research Site
    Okayama, 700-8558, Japan
  • Research Site
    Osaka, 541-8567, Japan
  • Research Site
    Osaka, 545-8586, Japan
  • Research Site
    Ota-shi, 373-8550, Japan
  • Research Site
    Sendai, 980-8574, Japan
  • Research Site
    Shinagawa-ku, 142-8666, Japan
  • Research Site
    Yokohama, 232-0024, Japan
  • Research Site
    Yokohama, 241-8515, Japan
  • Research Site
    Chihuahua City, 31210, Mexico
  • Research Site
    Cuernavaca, 62290, Mexico
  • Research Site
    Mérida, 97134, Mexico
  • Research Site
    Monterrey, 66220, Mexico
  • Research Site
    Veracruz, 91851, Mexico
  • Research Site
    Katowice, 40-074, Poland
  • Research Site
    Krakow, 31-115, Poland
  • Research Site
    Lodz, 90-513, Poland
  • Research Site
    Siedlce, 08-110, Poland
  • Research Site
    Warsaw, 02-034, Poland
  • Research Site
    Chelyabinsk, 454087, Russia
  • Research Site
    Krasnodar, 350040, Russia
  • Research Site
    Moscow, 115478, Russia
  • Research Site
    Obninsk, 249031, Russia
  • Research Site
    Saint Petersburg, 197758, Russia
  • Research Site
    Tyumen, 6250041, Russia
  • Research Site
    Ufa, 450054, Russia
  • Research Site
    Yekaterinburg, 620905, Russia
  • Research Site
    Daegu, 41404, South Korea
  • Research Site
    Seoul, 06273, South Korea
  • Research Site
    Seoul, 06351, South Korea
  • Research Site
    Seoul, 138-736, South Korea
  • Research Site
    Suwon, 16247, South Korea
  • Research Site
    Barcelona, 8035, Spain
  • Research Site
    Córdoba, 14004, Spain

Showing the first 100 of 133 sites across 16 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2020 (actual). Primary completion is estimated for Jun 2027, 80 months after the start.

Of 44 phase 3 interventional studies under Esophageal Squamous Cell Carcinoma, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 76. This study's planned 80 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2020
First posted
Sep 16, 2020
StartActual
Oct 19, 2020
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2027
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and site details
1 update, last Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Minor edits only
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04550260
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Sep 16, 2020
Start date
Oct 19, 2020
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Oct 13, 2026

Study contacts

Luhua Wang, MD
principal investigator · Cancer Hospital of Chinese Academy of Medical Science
Nabil Saba, MD
principal investigator · Department of Hematology and Medical Oncology, Emory University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Durvalumab

Start the discussion